Principles of drug discovery
Download as PPTX, PDF96 likes26,560 views
The document discusses the principles and process of drug discovery, which involves identifying a target, screening compounds, preclinical testing, and clinical trials. It takes an average of 12-15 years and $600-800 million to bring a new drug to market. Key stages include target identification and validation, screening compounds through various techniques, preclinical studies in animals, and clinical trials in phases I-III to test safety and efficacy in humans. Novel approaches like microarrays, peptidomimetics, pharmacogenomics, and cheminformatics can aid the drug discovery process.
More Related Content
Similar to Principles of drug discovery (20)
More from pharmacologyseminars (20)
Principles of drug discovery
- 1. Principles of drug discovery : by kavya lakshmi.v (Pharmacology) Under the guidance of : Dr T.Vedhavathi Mpharm ;PhDCmr collage of pharmacy
- 2. Principles of drug discovery
- 3. Drug discoveryDef: The process of drug discovery involves the identification of lead and its targets, synthesis, characterization, screening, and assays for therapeutic efficacy of lead. Once a compound has shown its value in in these tests, it will begin the process of drug development prior to clinical trails.The average time required to bring a drug to the market range from 12–15 years at an average cost of $600–800 million
- 4. Stages in drug discovery Drug discovery Formulation Preclinical studiesClinical trailsAny drug development process must proceed through several stagesin order to produce a product that is safe, efficacious, and has passed all regulatory requirements.
- 5. Process of drug discovery
- 6. Drug developmentTarget :Naturally existing cellular or molecular structure involved in the disease pathology on which the drug actsTargets TypesTarget validation :Involves demonstrating that a molecular target is critically involved in a disease process & modulation of the target is likely to have a therapeutic effect
- 7. Screening & designScreening :Investigation of a great number of compounds for a particular problem or feature of them RandomScreening Non-random Cross Random involves no intellectualization & assays are done with out structural regardsNon-random also known as targeted or focused & more narrow approach. compounds having a vague resemblance to weakly active compounds uncovered in a random screened Whether the "hits" against the chosen target will interfere with other related targets - this is the process of cross-screening
- 8. Techniques in screeningHigh through put screening :ideal technique which involves the molecule finding in such a way that hits only the chosen target even not the related It is often done for a molecule which already has some of the desired propertiesVirtual high through put screening : where screening is done using computer-generated models and attempting to "dock" virtual libraries to a target, are also often used.This is hit-lead phase is followed
- 9. Approches Nature of sources Chemical sourcesRational approchesMolecular modelling Combnitorial chemistryBiotechnologyBioinformatics Preclinical studiesClinicaltrails
- 10. Nature of sourcePlant species provide a potenial source of strating or crude material for the drug discovery
- 11. Many cardiotonics are plant derived
- 12. Microbes are the main source of antimicrobial drugs
- 13. Streptomyces species have been a source of antibiotics.
- 14. Marine environments are potential sources for new bioactive agents.
- 15. Arabinose neucleosides discovered from marine invertebatesChemical sourceThese include semisynthetic drugsIt has organic and inorganic sourcesMineral resources are one of it.New source of chemical synthesis is Combinatorial ChemistryCombinatorial chemistry: involves the synthesis or biosynthesis of chemical libraries (a family of compounds having a certain base chemical structure) of molecules with in a short period of time for the purpose of biological screening, particularly for lead discovery or lead modification.
- 16. MethodsThere different types of combinatorial synthesis combinatorial synthesis
- 17. Split Synthesis: Peptide Libraries
- 18. Encoding Combinatorial Libraries
- 19. Nonpeptide LibrariesThe main differences among the various combinatorial approaches are the solid support used, the methods for assembling the building blocks, the state (immobilized or in solution) and numbers (a fraction of the total library or individual entities)
- 21. Molecular modelingStructure Modifications to Increase Potency and the Therapeutic Index 1 Homologation 2 Chain Branching 3 Ring-Chain Transformations 4 Bioisosterism5 SAR by NMR/SAR by MS6 CADD
- 22. Homologation : prolongation of saturated carbon chain with groups that differ by a constant unit to increase pharmacological effect & lipophilicityChain branching :this involves the side branching of alkyl groups instead of long straight chain alkyl groupsRing chain transformation :effective pharmacokinetic properties are obtained by transformation of alkyl substituent's into cyclic analogsBioisosterism :Bioisosterism is an important lead modification approach that has been shown to be useful to attenuate toxicity or to modify the activity of a lead
- 23. SAR/NMR :This approach, termed SAR by NMR, was initially used to discover compounds with nanomolar affinitiess by tethering two molecules with micro molar affinities (low potency). CADD :Computer-aided design (CAD), also known as computer-aided design and drafting (CADD) , is the use of computer technology for the process of design and design-documentation. Computer Aided Drafting describes the process of drafting with a computer
- 25. Preclinical studiesAcute Studies :The goal is to determine toxic dose levels and observe clinical indications of toxicity. Data from acute toxic studies helps determine doses for repeated dose studies in animals and Phase I studies in humans. Repeated Dose Studies :These are repeated dose studies may be referred to as sub acute, sub chronic, or chronic. The specific duration should anticipate the length of the clinical trial that will be conducted on the new drug. Again, two species are typically required. Genetic Toxicity Studies :These studies assess the likelihood that the drug compound is mutagenic or carcinogenic.
- 26. Reproductive Toxicity Studies : Segment I reproductive toxic studies look at the effects of the drug on fertility. Segment II and III studies detect effects on embryonic and post-natal developmentCarcinogenicity Studies :Carcinogenicity studies are usually needed only for drugs intended for chronic or recurring conditionsToxicokinetic Studies :These are typically similar in design to PK/ADME studies except that they use much higher dose levels. They examine the effects of toxic doses of the drug and help estimate the clinical margin of safety
- 27. Preclinical studies & Clinical trails
- 28. Clinical trails
- 29. Clinical trailsPhase I:No blinding screening,open label & done in single centre
- 30. Phase II :Therapeutic exploration & dose rangingMay be blind or open label (4centre’s or more)
- 31. Phase III :Therapeutic confirmation or comparison Done in multicentre
- 32. Post marketing surveillance : study of uncommon or idiosyncratic ADR dose who occur only after long term use & unsuspected drug interactions Patients treated in the normal course form the study population It includes special cases like pediatrics ,pregnant women renal & hepatic diseased persons who are excluded in the previous stages of clinical trailsModification drug delivery systems ,route of administration, fixed drug doses ,drug combinations etc are explored here
- 33. Novel approachesMicro array techniquesPeptidomimeticsPharmacogenomics ProteomicsChemi-informatics
- 34. Conclusion
- 35. Queries
Editor's Notes
- #4: < 2% of new compounds investigated may show suitable biological activityModification of an existing drug can yield as little as 1% suitable compounds< 10% of these compounds result in successful human clinical trials and reaches the market place
- #6: Health insurance portability n accountabilityProduct devolp n management associatnCentral drug stndrd controlorganisation